Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY19 results · Jan–Mar 2019
Aarti Drugs reported revenue from operations of ₹459.14 crore and net profit of ₹27.44 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 459.14 | — | — | 380.10 | +20.8% |
| Other income | 4.99 | — | — | 0.17 | 29x |
| Total income | 464.13 | — | — | 380.27 | +22.1% |
| Profit before tax | 39.75 | — | — | 30.83 | +28.9% |
| Net profit for the period | 27.44 | — | — | 20.89 | +31.4% |
| EPS, basic (₹) | 12.06 | — | — | 8.86 | +36.1% |
| Net margin (%) | 6.0 | — | 5.5 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 432.54 | — | — | 350.65 | +23.4% |
| Other income | 5.03 | — | — | 0.21 | 24x |
| Total income | 437.57 | — | — | 350.86 | +24.7% |
| Profit before tax | 37.51 | — | — | 31.05 | +20.8% |
| Net profit for the period | 25.69 | — | — | 21.15 | +21.5% |
| EPS, basic (₹) | 11.31 | — | — | 8.97 | +26.1% |
| Net margin (%) | 5.9 | — | 6.0 |
Consolidated
- Filed with BSE
- 16 May 2019, 17:53 IST
- Board meeting
- 15 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 May 2019, 17:53 IST
- Board meeting
- 15 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE